Keywords: sanofi-aventis, buys, market, rights, aeterna, zentaris, cetrorelix
Sanofi-Aventis buys US market rights to AEterna Zentaris' cetrorelix for up to $165M
Article | 16 March 2009
AEterna Zentaris, a Canadian biopharmaceutical firm focused on endocrine therapy and oncology, has signed a development, commercialization and licensing agreement ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- US Supreme Court says patent settlement can "sometimes" be illegal
- InSite Vision joins Merck & Co and Pfizer in patent infringement law suit against
- Osteoporosis drug bazedoxifene stops growth of breast cancer cells, even in resistant tumors
- Additional indications in Japan for Roche's Avastin and Astellas' Prograf
- Highlights of EHA meeting: Novartis' Jakavi; Bristol-Myers and AbbVie's elotuzumab; Janssen's ibrutinib
